Strategy

Special Guest Op-Ed: What a decade of collaboration and shared effort reveals about the future of drug development.

The shifting landscape amid China's biotech rises presents both opportunities and geopolitical challenges for growth strategies.

Ken Banta and Andrew Hall share insights on leading through uncertainty—covering culture, capital, risk, and the regulatory headwinds influencing key decisions in drug development.

By giving small and mid-size biotechs access to real-world data and advanced analytics once reserved for large pharma, AI platforms are leveling the playing field by enabling lean teams to de-risk clinical strategy, strengthen fundraising narratives, and make faster, more confident decisions across the development lifecycle.

How to optimize a pharma location strategy in unheralded but rich regions for biotech talent around the world.

EVERSANA president Greg Skalicky continues the conversation, providing details about the commercialization strategy.

Precigen's president and CEO discusses the recent launch of Papzimeos.

The AI dilemma facing biopharma—and what’s at risk.

Clarivate’s Drugs to Watch 2026 report highlights Eli Lilly’s late-stage cardiometabolic candidates orforglipron and retatrutide as the clear standouts in an obesity and diabetes market projected to reach $150 billion by 2035.

Can generics be liable for induced infringement despite carve-outs?

When approaching cell and gene therapies (CGT), investors want to back companies that demonstrate operational foresight. Here are five levers for building a CGT operating model that can tackle the category’s unique commercialization complexities.

Jim Greffet, head of sustainability at Eli Lilly, on establishing ESG as a core business driver—and key complement to manufacturer long-term growth pursuits.

As the availability and utilization of ultra-high-cost, long-term specialty products such as GLP-1s and cell and gene therapies grows, HR decision-makers and pharmacy consultants must embrace a more value-oriented mindset where they can.

Inside Brent Saunders’ return run as CEO of Bausch + Lomb—and setting the storied eye care pharma on a bold path of reinvention.

Ascension of agonist class touching all parts of the market—from science to strategy.

Experts weigh in on FDA’s new accelerated review program, revealing what companies stand to benefit the most from the initiative.

With patent cliffs fast approaching, asset differentiation will be king.

Amid the US reshoring push, drugmakers navigate geopolitical and supply chain risks.

Why the new wave of direct-to-consumer access represents more than a passing trend.

Will the politically fueled reforms and mandates around drug pricing reduce the complexity of the system?

Welcome to Pharm Exec's new guest column on navigating the geopolitical risks challenging core company strategies in today's shifting global landscape for healthcare.

A successful transition from clinical development to commercial launch in cell and gene therapy requires early, structured collaboration with health systems to address operational, financial, and workflow challenges that shape real-world patient access and therapy adoption.

Moderna secures a $1.5 billion loan to enhance financial flexibility while targeting a 10% revenue growth by 2026, focusing on innovative mRNA therapies.

The first wave of Commissioner’s National Priority Vouchers signals a fundamental shift in FDA competitiveness, rewarding companies that pair breakthrough science with affordability commitments, onshore manufacturing readiness, and the operational muscle to execute ultra-accelerated reviews.

The FDA’s new Commissioner’s National Priority Voucher signals a transformative shift in U.S. drug review, tying accelerated approval to manufacturing readiness, domestic supply-chain strength, and credible affordability commitments, while redefining how companies must innovate, scale, and launch therapies in 2025 and beyond.